Infliximab (Remicade)

DRUG5 trials

Sponsors

Center for Integrated Rehabilitation and Organ Failure Horn, Centocor, Inc., University of California, San Diego, Merck Sharp & Dohme LLC, Biocad

Conditions

Ankylosing SpondylitisArthritis, RheumatoidCOPDCachexiaCrohn DiseaseKawasaki DiseasePsoriasis

Phase 1

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

CompletedNCT00271570

University of California, San DiegoKawasaki Disease

Start: 2004-04-30End: 2006-10-31Updated: 2010-06-14

Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

CompletedNCT02359903

BiocadAnkylosing Spondylitis

Start: 2015-02-28End: 2015-11-30Updated: 2016-06-08

Phase 2

Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia

CompletedNCT00244192

Center for Integrated Rehabilitation and Organ Failure HornCachexia, COPD

Start: 2003-10-31End: 2005-12-31Target: 16Updated: 2005-12-09

Phase 4

Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)

CompletedNCT00794898

Merck Sharp & Dohme LLCArthritis, Rheumatoid

Start: 2003-07-01End: 2004-04-01Updated: 2017-03-28

Unknown Phase

A Long-term Safety Study of Infliximab (Remicade)

CompletedNCT00261976

Centocor, Inc.Arthritis, Rheumatoid, Crohn Disease, Psoriasis

Start: 2002-02-28End: 2012-03-31Updated: 2014-03-18